{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:39:05Z","timestamp":1792471145301,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hered Cancer Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Risk-reducing mastectomy (RRM) for germline pathogenic variant (GPVs) carriers were historically performed as total mastectomy (TM) or skin-sparing mastectomy (SSM), although nipple-sparing mastectomy (NSM) has recently emerged as an oncologically safe RRM option.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective cohort study included all female patients with confirmed\n                      <jats:italic>BRCA1<\/jats:italic>\n                      ,\n                      <jats:italic>BRCA2<\/jats:italic>\n                      ,\n                      <jats:italic>PALB2<\/jats:italic>\n                      , or other high-penetrance GPVs at two academic institutions in Canada between 2003 and 2024. Temporal trends in NSM uptake were assessed using the Mantel-Haenszel test for trend and multivariable logistic regression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After exclusions, 559 GPV carriers including 319 (57%) affected carriers and 240 (43%) unaffected carriers comprised the study cohort. The median age at RRM was 45 years old (range 22\u201376) and most were\n                      <jats:italic>BRCA1<\/jats:italic>\n                      carriers (46.7%) or\n                      <jats:italic>BRCA2<\/jats:italic>\n                      carriers (44.4%). Overall, 310 carriers (55.5%) underwent NSM, 174 (31.1%) underwent SSM, and 75 (13.4%) underwent TM. NSM uptake was highest among patients aged 40\u201349 years (56%) and lowest in those\u2009\u2265\u200960 years (42%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03). Relative to unaffected carriers, affected carriers (47% vs. 66%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and those with prior radiation were less likely to undergo NSM (34.3% vs. 62.7%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). A clear increase in NSM occurred over time, from 11.9% pre-2012 to 74.4% after 2022 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Multivariable analysis adjusting for age, GPV, parity, menopausal status, and personal history of breast cancer identified normal BMI (OR 1.99, 95% CI 1.18\u20133.34), lack of radiation exposure (OR 3.03, 95% CI 1.76\u20135.23), and year of surgery as independent predictors of NSM receipt (OR 1.25, 95% CI 1.19\u20131.32).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      There has been a significant increase in NSM use among\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      ,\n                      <jats:italic>PALB2<\/jats:italic>\n                      and other GPV carriers over the last two decades.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13053-026-00351-0","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T09:26:04Z","timestamp":1784885164000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trends in the uptake of nipple sparing mastectomy in BRCA1\/2, PALB2 and other pathogenic variant carriers undergoing risk reducing mastectomy"],"prefix":"10.1186","volume":"24","author":[{"given":"Marya","family":"Alsuhaibani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amel","family":"Melanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Viezel-Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tassos","family":"Dionisopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Basik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Francois","family":"Boileau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karyne","family":"Martel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarkis","family":"Meterissian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Vorstenbosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Villareal-Corpuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Foulkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ipshita","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6850-2192","authenticated-orcid":false,"given":"Stephanie M.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"351_CR1","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317:2402\u201316.","journal-title":"JAMA"},{"key":"351_CR2","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1200\/JCO.19.01907","volume":"38","author":"X Yang","year":"2020","unstructured":"Yang X, Leslie G, Doroszuk A, et al. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. J Clin Oncol. 2020;38:674\u201385.","journal-title":"J Clin Oncol"},{"key":"351_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1056\/NEJM199901143400201","volume":"340","author":"LC Hartmann","year":"1999","unstructured":"Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340:77\u201384.","journal-title":"N Engl J Med"},{"key":"351_CR4","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1093\/jnci\/93.21.1633","volume":"93","author":"LC Hartmann","year":"2001","unstructured":"Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93:1633\u20137.","journal-title":"J Natl Cancer Inst"},{"key":"351_CR5","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1016\/j.ejso.2021.03.248","volume":"47","author":"T Lozar","year":"2021","unstructured":"Lozar T, Zgajnar J, Perhavec A, et al. Trends and timing of risk-reducing mastectomy uptake in unaffected BRCA1 and BRCA2 carriers in Slovenia. Eur J Surg Oncol. 2021;47:1900\u20136.","journal-title":"Eur J Surg Oncol"},{"key":"351_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41416-019-0446-1","volume":"121","author":"K Metcalfe","year":"2019","unstructured":"Metcalfe K, Eisen A, Senter L, et al. International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. Br J Cancer. 2019;121:15\u201321.","journal-title":"Br J Cancer"},{"key":"351_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/tbj.12542","volume":"22","author":"CH Wei","year":"2016","unstructured":"Wei CH, Scott AM, Price AN, et al. Psychosocial and Sexual Well-Being Following Nipple-Sparing Mastectomy and Reconstruction. Breast J. 2016;22:10\u20137.","journal-title":"Breast J"},{"key":"351_CR8","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1245\/s10434-014-3883-3","volume":"22","author":"K Yao","year":"2015","unstructured":"Yao K, Liederbach E, Tang R, et al. Nipple-sparing mastectomy in BRCA1\/2 mutation carriers: an interim analysis and review of the literature. Ann Surg Oncol. 2015;22:370\u20136.","journal-title":"Ann Surg Oncol"},{"key":"351_CR9","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10549-008-0238-4","volume":"118","author":"F Didier","year":"2009","unstructured":"Didier F, Radice D, Gandini S, et al. Does nipple preservation in mastectomy improve satisfaction with cosmetic results, psychological adjustment, body image and sexuality? Breast Cancer Res Treat. 2009;118:623\u201333.","journal-title":"Breast Cancer Res Treat"},{"key":"351_CR10","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1245\/s10434-018-6585-4","volume":"25","author":"A Romanoff","year":"2018","unstructured":"Romanoff A, Zabor EC, Stempel M, et al. A Comparison of Patient-Reported Outcomes After Nipple-Sparing Mastectomy and Conventional Mastectomy with Reconstruction. Ann Surg Oncol. 2018;25:2909\u201316.","journal-title":"Ann Surg Oncol"},{"key":"351_CR11","doi-asserted-by":"publisher","first-page":"5657","DOI":"10.1245\/s10434-021-10445-9","volume":"28","author":"M Garstka","year":"2021","unstructured":"Garstka M, Henriquez A, Kelly BN, et al. How Protective are Nipple-Sparing Prophylactic Mastectomies in BRCA1 and BRCA2 Mutation Carriers? Ann Surg Oncol. 2021;28:5657\u201362.","journal-title":"Ann Surg Oncol"},{"key":"351_CR12","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/bjs.11616","volume":"107","author":"MG Valero","year":"2020","unstructured":"Valero MG, Moo TA, Muhsen S, et al. Use of bilateral prophylactic nipple-sparing mastectomy in patients with high risk of breast cancer. Br J Surg. 2020;107:1307\u201312.","journal-title":"Br J Surg"},{"key":"351_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1001\/jamasurg.2017.3422","volume":"153","author":"JW Jakub","year":"2018","unstructured":"Jakub JW, Peled AW, Gray RJ, et al. Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations: A Multi-institutional Study. JAMA Surg. 2018;153:123\u20139.","journal-title":"JAMA Surg"},{"key":"351_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10549-006-9487-2","volume":"106","author":"JE Rusby","year":"2007","unstructured":"Rusby JE, Brachtel EF, Michaelson JS, et al. Breast duct anatomy in the human nipple: three-dimensional patterns and clinical implications. Breast Cancer Res Treat. 2007;106:171\u20139.","journal-title":"Breast Cancer Res Treat"},{"key":"351_CR15","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/j.1524-4741.2008.00623.x","volume":"14","author":"JE Rusby","year":"2008","unstructured":"Rusby JE, Kirstein LJ, Brachtel EF, et al. Nipple-sparing mastectomy: lessons from ex vivo procedures. Breast J. 2008;14:464\u201370.","journal-title":"Breast J"},{"key":"351_CR16","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1245\/s10434-019-07554-x","volume":"26","author":"SM Wong","year":"2019","unstructured":"Wong SM, Chun YS, Sagara Y, et al. National Patterns of Breast Reconstruction and Nipple-Sparing Mastectomy for Breast Cancer, 2005\u20132015. Ann Surg Oncol. 2019;26:3194\u2013203.","journal-title":"Ann Surg Oncol"},{"key":"351_CR17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.suronc.2019.04.009","volume":"29","author":"O Grinstein","year":"2019","unstructured":"Grinstein O, Krug B, Hellmic M, et al. Residual glandular tissue (RGT) in BRCA1\/2 germline mutation carriers with unilateral and bilateral prophylactic mastectomies. Surg Oncol. 2019;29:126\u201333.","journal-title":"Surg Oncol"},{"key":"351_CR18","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1245\/s10434-014-3532-x","volume":"21","author":"HL Baltzer","year":"2014","unstructured":"Baltzer HL, Alonzo-Proulx O, Mainprize JG, et al. MRI volumetric analysis of breast fibroglandular tissue to assess risk of the spared nipple in BRCA1 and BRCA2 mutation carriers. Ann Surg Oncol. 2014;21:1583\u20138.","journal-title":"Ann Surg Oncol"},{"key":"351_CR19","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1245\/s10434-015-4737-3","volume":"22","author":"AC Krajewski","year":"2015","unstructured":"Krajewski AC, Boughey JC, Degnim AC, et al. Expanded Indications and Improved Outcomes for Nipple-Sparing Mastectomy Over Time. Ann Surg Oncol. 2015;22:3317\u201323.","journal-title":"Ann Surg Oncol"},{"key":"351_CR20","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s13304-020-00796-5","volume":"72","author":"E Barbieri","year":"2020","unstructured":"Barbieri E, Frusone F, Bottini A, et al. Evolution and time trends of nipple-sparing mastectomy: a single-center experience. Updates Surg. 2020;72:893\u20139.","journal-title":"Updates Surg"},{"key":"351_CR21","doi-asserted-by":"crossref","unstructured":"Weber WP, Haug M, Kurzeder C, et al. Oncoplastic breast consortium consensus conference on nipple-sparing mastectomy. Breast Cancer Res Treat. 2018;172:523\u2013537.","DOI":"10.1007\/s10549-018-4937-1"},{"key":"351_CR22","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1093\/bjs\/znad107","volume":"110","author":"TA Moo","year":"2023","unstructured":"Moo TA, Nelson JA, Sevilimedu V, et al. Strategies to avoid mastectomy skin-flap necrosis during nipple-sparing mastectomy. Br J Surg. 2023;110:831\u20138.","journal-title":"Br J Surg"},{"key":"351_CR23","doi-asserted-by":"publisher","first-page":"7791","DOI":"10.1097\/JS9.0000000000002155","volume":"110","author":"Y Kook","year":"2024","unstructured":"Kook Y, Kim D, Park S, et al. Nipple-areolar complex sensory recovery based on incision placement after nipple-sparing mastectomy: a prospective nonrandomized controlled trial. Int J Surg. 2024;110:7791\u20137.","journal-title":"Int J Surg"},{"key":"351_CR24","doi-asserted-by":"publisher","first-page":"e906","DOI":"10.1097\/PRS.0000000000005502","volume":"143","author":"DA Daar","year":"2019","unstructured":"Daar DA, Abdou SA, Rosario L, et al. Is There a Preferred Incision Location for Nipple-Sparing Mastectomy? A Systematic Review and Meta-Analysis. Plast Reconstr Surg. 2019;143:e906\u201319.","journal-title":"Plast Reconstr Surg"},{"key":"351_CR25","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1245\/s10434-015-4669-y","volume":"22","author":"R Tang","year":"2015","unstructured":"Tang R, Coopey SB, Colwell AS, et al. Nipple-Sparing Mastectomy in Irradiated Breasts: Selecting Patients to Minimize Complications. Ann Surg Oncol. 2015;22:3331\u20137.","journal-title":"Ann Surg Oncol"},{"key":"351_CR26","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/PRS.0000000000000466","volume":"134","author":"H Sbitany","year":"2014","unstructured":"Sbitany H, Wang F, Peled AW, et al. Immediate implant-based breast reconstruction following total skin-sparing mastectomy: defining the risk of preoperative and postoperative radiation therapy for surgical outcomes. Plast Reconstr Surg. 2014;134:396\u2013404.","journal-title":"Plast Reconstr Surg"},{"key":"351_CR27","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1097\/PRS.0000000000001129","volume":"135","author":"RG Reish","year":"2015","unstructured":"Reish RG, Lin A, Phillips NA, et al. Breast reconstruction outcomes after nipple-sparing mastectomy and radiation therapy. Plast Reconstr Surg. 2015;135:959\u201366.","journal-title":"Plast Reconstr Surg"},{"key":"351_CR28","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.amjsurg.2019.12.011","volume":"220","author":"C Webb","year":"2020","unstructured":"Webb C, Gupta N, Kosiorek H, et al. The effects of body mass index on operative time and outcomes in nipple-sparing mastectomy. Am J Surg. 2020;220:395\u2013400.","journal-title":"Am J Surg"},{"key":"351_CR29","doi-asserted-by":"publisher","first-page":"e795","DOI":"10.1097\/PRS.0000000000004404","volume":"141","author":"JD Frey","year":"2018","unstructured":"Frey JD, Salibian AA, Karp NS, et al. The Impact of Mastectomy Weight on Reconstructive Trends and Outcomes in Nipple-Sparing Mastectomy: Progressively Greater Complications with Larger Breast Size. Plast Reconstr Surg. 2018;141:e795\u2013804.","journal-title":"Plast Reconstr Surg"},{"key":"351_CR30","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1097\/01.prs.0000438056.67375.75","volume":"133","author":"AS Colwell","year":"2014","unstructured":"Colwell AS, Tessler O, Lin AM, et al. Breast reconstruction following nipple-sparing mastectomy: predictors of complications, reconstruction outcomes, and 5-year trends. Plast Reconstr Surg. 2014;133:496\u2013506.","journal-title":"Plast Reconstr Surg"},{"key":"351_CR31","doi-asserted-by":"crossref","unstructured":"Melanson A, Alsuhaibani M, Viezel-Mathieu A, et al. Trends in breast reconstruction for BRCA1\/2, PALB2 and other high penetrance germline pathogenic variant carriers undergoing risk reducing mastectomy. Fam Cancer. 2026;25.","DOI":"10.1007\/s10689-026-00564-1"},{"key":"351_CR32","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa1400382","volume":"371","author":"AC Antoniou","year":"2014","unstructured":"Antoniou AC, Foulkes WD, Tischkowitz M. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371:1651\u20132.","journal-title":"N Engl J Med"},{"key":"351_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","volume":"34","author":"C Sessa","year":"2023","unstructured":"Sessa C, Balmana J, Bober SL, et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Ann Oncol. 2023;34:33\u201347.","journal-title":"Ann Oncol"},{"key":"351_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","volume":"19","author":"MB Daly","year":"2021","unstructured":"Daly MB, Pal T, Berry MP, et al. Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19:77\u2013102.","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Hereditary Cancer in Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13053-026-00351-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-026-00351-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-026-00351-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:56:37Z","timestamp":1792468597000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13053-026-00351-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["351"],"URL":"https:\/\/doi.org\/10.1186\/s13053-026-00351-0","relation":{},"ISSN":["1897-4287"],"issn-type":[{"value":"1897-4287","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"30 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Institutional review board approvals were obtained from the Jewish General Hospital (CIUSSS West-Central Montreal Research Ethics Board, reference no. MP-05-2024-3780) and McGill University Health Centre (CIUSSS Central West of the Island of Montreal Research Ethics board). Due to the use of retrospective, de-identified data obtained from the medical record, consent from participants was deemed unnecessary.","order":1,"name":"Ethics","label":"Ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"21"}}